In July of this year, the American Academy of Pediatrics (AAP)released revised recommendations for the management of hypercholesterolemiain children (see table).1 Within days after publication, thenew policy statement had elicited a firestorm of controversy— including hundreds of print and broadcast news stories,editorials in the New York Times and the Boston Globe, and thousandsof Internet postings — that took many members of the pediatricscommunity by surprise. The AAP and the National CholesterolEducation Program have advocated targeted screening and pharmacologictreatment for nearly two decades. What sparked this sudden flurryof media attention?
Dr. de Ferranti is director of the Preventive Cardiology Clinic at Children's Hospital Boston and an assistant professor of pediatrics at Harvard Medical School, in Boston. Dr. Ludwig is director of the Optimal Weight for Life Program at Children's Hospital Boston and an associate professor of pediatrics at Harvard Medical School.
This article has been cited by other articles:
Baumer, J H, Shield, J P H
(2009). Hypercholesterolaemia in children guidelines review. EDUCATION AND PRACTICE
94: 84-86
[Full Text]
Daniels, S. R.
(2009). Use of Pharmacologic Agents for Treatment of Diabetes Mellitus, Dyslipidemia, and Hypertension in Children and Adolescents. Arch Pediatr Adolesc Med
163: 389-391
[Full Text]
